Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2020 Financial Results and Business Updates

Rhea-AI Summary

Mersana Therapeutics (NASDAQ:MRSN) announced an upcoming conference call on August 7, 2020, at 8:00 a.m. ET to discuss its financial results for Q2 2020, ending June 30. The company specializes in developing antibody-drug conjugates (ADCs) for high unmet medical needs in cancer treatment. Mersana's lead candidate, XMT-1536, is advancing through clinical trials for ovarian cancer and non-small cell lung cancer (NSCLC). The company is also progressing with XMT-1592, targeting NaPi2b-expressing tumors. More information is available on their website.

Positive

• Mersana's lead candidate, XMT-1536, is in Phase 1 clinical trials for ovarian cancer and NSCLC.
• XMT-1592 is in the dose escalation phase of clinical trials, targeting NaPi2b-expressing tumors.
• Multiple partners are leveraging Mersana's Dolaflexin platform for ADC development.

Negative

• None.

CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Friday, August 7, 2020 at 8:00 a.m. ET to report financial results for the second quarter ended June 30, 2020 and provide business updates. 

To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 1081289. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com. 

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.

Contact:

Investor & Media Contact
Sarah Carmody, 617-844-8577
scarmody@mersana.com 

FAQ

What is the date of Mersana Therapeutics' Q2 2020 earnings call?

The Q2 2020 earnings call is scheduled for August 7, 2020.

What financial results will Mersana Therapeutics report on August 7, 2020?

Mersana will report its financial results for the second quarter ended June 30, 2020.

What are the key product candidates of Mersana Therapeutics?

Mersana's key product candidates include XMT-1536 and XMT-1592.

How can I access the webcast for Mersana's earnings call?

The webcast can be accessed via the Investors & Media section of Mersana's website.